St. Jude Care & Treatment

Menu

Close

Recruiting

INITIALL: Risk-based Pediatric Leukemia/Lymphoma Treatment

About this study

The standard treatment for acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LLy, a type of non-Hodgkin lymphoma), and mixed phenotype acute leukemia/lymphoma (MPAL) is chemotherapy. The treatment usually uses 4–7 chemotherapy drugs during the first part of treatment.

This study will collect the blood, bone marrow, and tissue samples we need to properly diagnose and classify a child’s leukemia or lymphoma. We will study genetic changes in these samples and do other tests. The treatment is risk-based. This means that a child’s treatment will be based on several leukemia- or lymphoma-specific features that can affect how well they respond to treatment.

The main goal of this study is to find out whether a child’s leukemia or lymphoma is low-risk, standard-risk, or high-risk. The term “risk” refers to the chance of the cancer coming back during or after treatment. The child’s risk category will determine the treatment they will receive.

Eligibility overview

  • Ages 1–18 years
  • Acute lymphoblastic leukemia (ALL) with at least 25% bone marrow blasts or evidence of ALL in peripheral blood
  • Lymphoblastic lymphoma (LLy) with less than 25% bone marrow blasts and fewer than 1,000 circulating blasts per microL
  • Mixed phenotype acute leukemia (MPAL) with or without 25% bone marrow involvement 

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Study goal:

To find out whether a child’s leukemia or lymphoma is low-risk, standard-risk, or high-risk. The risk category will determine the treatment they will receive. 

Diagnosis:

Acute lymphoblastic leukemia, lymphoblastic leukemia,  mixed phenotype acute leukemia, lymphoblastic lymphoma (Non-Hodgkin lymphoma)

Age:

1--18 years

Clinical trials categories:

Childhood Cancer Lymphoma Leukemia Non-Hodgkin Lymphoma

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more